State Street SPDR S&P Biotech ETF
195 hedge funds and large institutions have $2.3B invested in State Street SPDR S&P Biotech ETF in 2016 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 59 reducing their positions, and 40 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 59
3% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 40
2% less funds holding
Funds holding: 199 → 195 (-4)
13.37% less ownership
Funds ownership: 132.39% → 119.02% (-13%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
25% less capital invested
Capital invested by funds: $3.05B → $2.3B (-$759M)
30% less call options, than puts
Call options by funds: $641M | Put options by funds: $913M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$121M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$110M |
| 3 |
O
OrbiMed
New York
|
+$51M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$44.2M |
| 5 |
Millennium Management
New York
|
+$20.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$308M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$51.5M |
| 3 |
JP Morgan Chase
New York
|
-$42.2M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$21M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$7.5M |
XBI Hedge Fund Activity: Q1 2016 in Review
195 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2016, worth a combined $2.3B — down 25% from $3.05B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of XBI and 39 opened new positions — a net loss of 1 holder — while 59 trimmed existing stakes and 64 added.
The largest buyer was Goldman Sachs, adding an estimated $121M. The largest seller was Morgan Stanley, cutting an estimated $308M.
- 195 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2016, down from 199 in Q4 2015.
- Funds reported $2.3B of State Street SPDR S&P Biotech ETF stock for Q1 2016, down 25% quarter-over-quarter.
- 39 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2016 and 40 closed out, a net change of -1 holder.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2016 was Goldman Sachs, an estimated $121M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2016 was Morgan Stanley, an estimated $308M sold.
Based on aggregated 13F filings for Q1 2016.